Systemic Juvenile Idiopathic Arthritis Clinical Trials 2022
Browse 6 SJIA Medical Studies Across 40 Cities
4 Phase 3 Trial · 80 SJIA Clinics
Reviewed by Michael Gill, B. Sc.
6 SJIA Clinical Trials Near Me
Top Hospitals for SJIA Clinical Trials
Cincinnati Children's Hospital Medical Center
Cincinnati
3Active Trials
9All Time Trials for SJIA
1994First SJIA Trial
Childrens Hospital Los Angeles
Los Angeles
2Active Trials
2All Time Trials for SJIA
2022First SJIA Trial
Northwestern University Feinberg School of Medicine Ann & Robert H Lurie Children's Hospital
Chicago
1Active Trials
1All Time Trials for SJIA
2022First SJIA Trial
Top Cities for SJIA Clinical Trials
Chicago
4Active Trials
Northwestern University Feinberg School of Medicine Ann & Robert H Lurie Children's HospitalTop Active Site
SJIA Clinical Trials by Phase of Trial
Phase 1 SJIA Clinical Trials
2Active SJIA Clinical Trials
2Number of Unique Treatments
18Number of Active Locations
SJIA Clinical Trials by Age Group
< 18 SJIA Clinical Trials
4Active SJIA Clinical Trials
Most Recent SJIA Clinical Trials
Top Treatments for SJIA Clinical TrialsClinical Trial
Began Recruiting Date
Phase
Treatment Name
Active SJIA Clinical Trials
All Time Trials for SJIA
First Recorded SJIA Trial
Ustekinumab
2
2
2022
Emapalumab
1
1
2018
AEVI-007 (CERC-007, AVTX-007)
1
1
2021
In open-label phase: treatment with tofacitinib
1
1
2018
Golimumab
1
2
2010
About The Author
Michael Gill - B. Sc.
First Published: October 23rd, 2021
Last Reviewed: November 13th, 2022
Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.
Relevant Clinical Trials
Top Oncology Trials
Popular Clinical Trials
References1 Leu JH, Shiff NJ, Clark M, Bensley K, Lomax KG, Berezny K, Nelson RM, Zhou H, Xu Z. Intravenous Golimumab in Patients with Polyarticular Juvenile Idiopathic Arthritis and Juvenile Psoriatic Arthritis and Subcutaneous Ustekinumab in Patients with Juvenile Psoriatic Arthritis: Extrapolation of Data from Studies in Adults and Adjacent Pediatric Populations. Paediatr Drugs. 2022 Sep 28. doi: 10.1007/s40272-022-00533-y. [Epub ahead of print] https://pubmed.ncbi.nlm.nih.gov/361715152 Leu JH, Shiff NJ, Clark M, Bensley K, Lomax KG, Berezny K, Nelson RM, Zhou H, Xu Z. Intravenous Golimumab in Patients with Polyarticular Juvenile Idiopathic Arthritis and Juvenile Psoriatic Arthritis and Subcutaneous Ustekinumab in Patients with Juvenile Psoriatic Arthritis: Extrapolation of Data from Studies in Adults and Adjacent Pediatric Populations. Paediatr Drugs. 2022 Nov;24(6):699-714. doi: 10.1007/s40272-022-00533-y. Epub 2022 Sep 28. https://pubmed.ncbi.nlm.nih.gov/361715153 Ruperto N, Brunner HI, Pacheco-Tena C, Louw I, Vega-Cornejo G, Spindler AJ, Kingsbury DJ, Schmeling H, Borzutzky A, Cuttica R, Inman CJ, Malievskiy V, Scott C, Keltsev V, Terreri MT, Viola DO, Xavier RM, Fernandes TAP, Velázquez MDRM, Henrickson M, Clark MB, Bensley KA, Li X, Lo KH, Leu JH, Hsu CH, Hsia EC, Xu Z, Martini A, Lovell DJ; Pediatric Rheumatology Collaborative Study Group (PRCSG) and the Paediatric Rheumatology International Trials Organisation (PRINTO) . Open-label phase 3 study of intravenous golimumab in patients with polyarticular juvenile idiopathic arthritis. Rheumatology (Oxford). 2021 Oct 2;60(10):4495-4507. doi: 10.1093/rheumatology/keab021. https://pubmed.ncbi.nlm.nih.gov/334933124 Ruperto N, Brunner HI, Pacheco-Tena C, Louw I, Vega-Cornejo G, Spindler AJ, Kingsbury DJ, Schmeling H, Borzutzky A, Cuttica R, Inman CJ, Malievskiy V, Scott C, Keltsev V, Terreri MT, Viola DO, Xavier RM, Fernandes TAP, Velázquez MDRM, Henrickson M, Clark MB, Bensley KA, Li X, Lo KH, Leu JH, Hsu CH, Hsia EC, Xu Z, Martini A, Lovell DJ; Pediatric Rheumatology Collaborative Study Group (PRCSG) and the Paediatric Rheumatology International Trials Organisation (PRINTO). Open-label phase 3 study of intravenous golimumab in patients with polyarticular juvenile idiopathic arthritis. Rheumatology (Oxford). 2021 Oct 2;60(10):4495-4507. doi: 10.1093/rheumatology/keab021. https://pubmed.ncbi.nlm.nih.gov/334933125 Ruperto N, Brunner HI, Pacheco-Tena C, Louw I, Vega-Cornejo G, Spindler AJ, Kingsbury DJ, Schmeling H, Borzutzky A, Cuttica R, Inman CJ, Malievskiy V, Scott C, Keltsev V, Terreri MT, Viola DO, Xavier RM, Fernandes TAP, Velázquez MDRM, Henrickson M, Clark MB, Bensley KA, Li X, Lo KH, Leu JH, Hsu CH, Hsia EC, Xu Z, Martini A, Lovell DJ; Pediatric Rheumatology Collaborative Study Group (PRCSG) and the Paediatric Rheumatology International Trials Organisation (PRINTO). Open-Label Phase 3 Study of Intravenous Golimumab in Patients With Polyarticular Juvenile Idiopathic Arthritis. Rheumatology (Oxford). 2021 Jan 25. pii: keab021. doi: 10.1093/rheumatology/keab021. [Epub ahead of print] https://pubmed.ncbi.nlm.nih.gov/33493312
Unbiased Results
We believe in providing patients with all the options.Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.Back to top
Conditions
Cancer Related
Treatments